Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ENDRA Life SciencesNDRA -2.09%19 Debt-to-Equity is 0.07 as of Jun. 2026, which is 13% below its 10-year median of 0.08. GuruFocus rates NDRA with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 181 Medical Diagnostics & Research companies, ENDRA Life Sciences ranks better than 51.93% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for ENDRA Life Sciences's Debt-to-Equity or its related term are showing as below:
NDRA'
s Debt-to-Equity Range Over the Past 10 Years
Min: -2.54 Med: 0.08 Max: 3.08
Current: 0.07
During the past 12 years, the highest Debt-to-Equity Ratio of ENDRA Life Sciences was 3.08. The lowest was -2.54. And the median was 0.08.
NDRA's Debt-to-Equity is ranked better than 51.93% of 181
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.28
vs NDRA: 0.07
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
ENDRA Life Sciences Debt-to-Equity Related Terms
ENDRA Life Sciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for ENDRA Life Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NDRA vs BIAF, MBAI, XWEL: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, ENDRA Life Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENDRA Life Sciences Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where ENDRA Life Sciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENDRA Life Sciences (NDRA) has a Debt-to-Equity of 0.07 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ENDRA Life Sciences and its competitors. This is 13% below median its historical median of 0.08. According to the industry distribution chart, ENDRA Life Sciences ranks #87 out of 181 companies in the Medical Diagnostics & Research industry, placing it in the top 48.1%.
Is ENDRA Life Sciences' Debt-to-Equity too high?
ENDRA Life Sciences' current Debt-to-Equity of 0.07 is 13% below median its 10-year median of 0.08. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.28. ENDRA Life Sciences' value of 0.07 is 75% below this industry median. Based on the distribution chart, ENDRA Life Sciences ranks #87 out of 181 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, ENDRA Life Sciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does ENDRA Life Sciences' Debt-to-Equity compare to BIAF and MBAI?
According to the Medical Diagnostics & Research industry distribution chart, ENDRA Life Sciences ranks #87 out of 181 companies for Debt-to-Equity. This puts ENDRA Life Sciences in the upper half of its industry. The industry median Debt-to-Equity is 0.28. ENDRA Life Sciences' value of 0.07 is 75% below this benchmark. While the company's 10-year median is 0.08 vs. the industry median of 0.28, ENDRA Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.28, based on 181 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ENDRA Life Sciences's current Debt-to-Equity of 0.07 is 75% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ENDRA Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ENDRA Life Sciences's current Debt-to-Equity is 0.07, which is 13% below median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENDRA Life Sciences stock overvalued right now?
ENDRA Life Sciences (NDRA) has a current Debt-to-Equity of 0.07. The current Debt-to-Equity is 0.07, which is 13% below median its 10-year median of 0.08 and 75% below the Medical Diagnostics & Research industry median of 0.28. ENDRA Life Sciences' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For ENDRA Life Sciences (NDRA), the current Debt-to-Equity is 0.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
19GF Score
Get the complete analysis for NDRA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NDRA has been successfully added to your 
